Treatment of Recurrent Hepatitis C after Liver Transplantation

• 作 者: SandeepMukherjee;
• 机 构: University of Nebraska Medical Center USA
• 出 处: 中国上海第七届国际新药发明科技年会
• 发表日期: 2009年期

　　Decompensated cirrhosis from hepatitis C (genotype 1) is the leading indication for liver transplantation in the United States accounting for approximately 50% of all liver transplants.Unfortunately,recurrent HCV is universal after LT and leads to cirrhosis in approximately 30% of patients after 5 years.Once cirrhosis develops,the risk of hepatic decompensation is 42% per year which has led to recurrent HCV emerging as an important yet controversial indication for liver retransplantation and renewed interest in the role of interferon-based therapies.